Celcuity

Celcuity Equity Ratio

The Equity Ratio of Celcuity (CELC) as of Oct 16, 2026 is 21.55 %. In the previous year, Equity Ratio was 47.17 % — a change of -54.31% (lower).

Equity Ratio

21.55 %

YoY

-54.31%

Last updated:

Equity Ratio of Celcuity is 2025 21.55 % . Equity Ratio of Celcuity was 2024 47.17 % . It decreases by -54.31% lower compared to the previous year.

The Celcuity Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
97.38 USD
Jan 1, 2019
95.15 USD
Jan 1, 2020
90.32 USD
Jan 1, 2021
79.98 USD
Jan 1, 2022
76.14 USD
Jan 1, 2023
73.09 USD
Jan 1, 2024
47.17 USD
Jan 1, 2025
21.55 USD
The Celcuity Equity Ratio history
YEAREquity RatioYoY
21.55 %-54.31%
47.17 %-35.47%
73.09 %-4.00%
76.14 %-4.81%
79.98 %-11.44%
90.32 %-5.08%
95.15 %-2.29%
97.38 %-0.83%
98.19 %+5.98%
92.65 %-2.12%
94.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celcuity Stock analysis

What does Celcuity do? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celcuity stock

Equity Ratio of Celcuity is 21.55 % in 2025.

Equity Ratio of Celcuity changed from 47.17 % to 21.55 %, representing a -54.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Celcuity since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Celcuity with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Celcuity

All Key Metrics — Celcuity